A Look at CRISPR Therapeutics’s (CRSP) Valuation Following First Public SyNTase Gene Editing Data Reveal

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of SyNTase preclinical data and could put a spotlight on the company's potential for tackling genetic diseases.

See our latest analysis for CRISPR Therapeutics.

Shares of CRISPR Therapeutics have seen modest momentum this year, as excitement around its SyNTase unveil and the recent dosing in a Phase 2 trial with Sirius Therapeutics signal a stream of scientific and clinical progress. While the 1-year total shareholder return stands at 0.6%, the drumbeat of innovation and strategic partnerships could help rekindle investor enthusiasm for the stock’s longer-term outlook.

If gene editing breakthroughs like SyNTase have sparked your interest, you might want to see what other biotech innovators are making headlines. Explore the full lineup in our See the full list for free..

With shares mostly treading water despite breakthroughs in the pipeline, the key question is whether CRISPR Therapeutics remains undervalued or if the market has already priced in the potential of SyNTase and its expanding partnerships.

Price-to-Book Ratio of 3.9x: Is It Justified?

CRISPR Therapeutics trades at a price-to-book ratio of 3.9x, notably higher than the US Biotechs industry average of 2.5x. This means the market is pricing CRSP stock at a significant premium to the value of its net assets when compared to sector peers.

The price-to-book ratio is a key gauge for early-stage biotechs like CRISPR Therapeutics that are not yet profitable. It reflects how much investors are willing to pay for every dollar of net asset value on the balance sheet. In this sector, it often serves as a proxy for future research and development potential and intellectual property bets. For CRSP, an elevated ratio indicates that the market has high expectations for future scientific or commercial breakthroughs, or is already factoring in potential revenue growth from SyNTase and other pipeline advances.

Compared to the US biotech sector average of 2.5x, CRISPR Therapeutics looks expensive. However, compared to its direct peer group, where the average price-to-book is 7.4x, it appears much cheaper. This split signals that the stock may be trading at a premium to most biotechs but at a relative discount against the companies it competes with most closely for innovation and capital. There is currently not enough data to determine a fair price-to-book ratio, which could serve as a more useful benchmark for long-term valuation potential.

Story Continues

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 3.9x (ABOUT RIGHT)

However, looming competition in gene editing and the persistent lack of profitability could temper optimism about CRISPR Therapeutics' valuation story.

Find out about the key risks to this CRISPR Therapeutics narrative.

Another View: DCF Analysis Suggests Upside

While CRISPR Therapeutics appears pricey compared to most biotechs using the price-to-book ratio, our SWS DCF model tells a different story. It estimates the company's fair value at $134.16 per share, considerably higher than the current price of $72.82. This suggests significant undervaluation if growth and cash flows materialize as projected. Does this disconnect point to real opportunity or lingering risks?

Look into how the SWS DCF model arrives at its fair value.CRSP Discounted Cash Flow as at Oct 2025

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own CRISPR Therapeutics Narrative

If you see the story unfolding differently or want to investigate the numbers for yourself, you can build your own take in just minutes. Do it your way

A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Don’t stop here. There’s a world of exciting opportunities waiting. Broaden your portfolio and get ahead of the curve by checking out these hand-picked stock ideas:

Target stable income streams by tapping into these 19 dividend stocks with yields > 3%, delivering consistent yields above 3% for income-focused investors. Ride the next tech wave with these 24 AI penny stocks, harnessing artificial intelligence for rapid innovation and industry disruption. Seize the growth potential behind these 26 quantum computing stocks, leading breakthroughs in quantum computing for tomorrow’s digital economy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CRSP.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments